DarioHealth Corp (DRIO)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $12.98M
Last updated: Nov 17, 2026 at 4:04 PM ET
DarioHealth Corp (DRIO) Stock Chart
DarioHealth (DRIO) has a latest price of $1.15 on Nov 17, 2026, 92.2% below its 52-week high of $14.77. Its price fell 90.2% over the past 12 months. The month-end price fell 99.8% over the 10 years through Oct 2026, a compound annual decline of 45.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $1,583.04 in Feb 2017 and its lowest $3.00 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart DRIO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for DRIO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 83.9%, and over 6 months it fell 86.0%. The month-end price fell 88.3% over the 3 years through Oct 2026, a compound annual decline of 51.1%.
| Period | Change |
|---|---|
| 1 month | -74.4% |
| 3 months | -83.9% |
| 6 months | -86.0% |
| 12 months | -90.2% |
| 12 months, with dividends | -90.2% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -88.3% | -51.1% |
| 5 years | -99.1% | -60.9% |
| 10 years | -99.8% | -45.4% |
Price by Year
Its best calendar year was 2020, when the price rose 117.8%, and its weakest was 2022, when it fell 67.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.00 | -73.6% |
| 2025 | $11.38 | -27.6% |
| 2024 | $15.72 | -54.3% |
| 2023 | $34.40 | -59.8% |
| 2022 | $85.60 | -67.0% |
| 2021 | $259.40 | -9.2% |
| 2020 | $285.80 | +117.8% |
| 2019 | $131.20 | -57.7% |
| 2018 | $310.40 | -51.6% |
| 2017 | $640.80 | -50.7% |
Trading Range
The price is 76.0% below its 50-day average of $4.78 and 84.0% below its 200-day average of $7.19.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.15 | |
| 52-week high | $14.77 | -92.2% |
| 52-week low | $1.09 | +5.5% |
| 50-day average | $4.78 | -76.0% |
| 200-day average | $7.19 | -84.0% |
Price Risk
Over 3 years, its largest fall from a peak was 97.8%.
| Measure | Value |
|---|---|
| 1-year beta | 0.16 |
| Largest fall, 1 year | -91.8% |
| Largest fall, 3 years | -97.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About DRIO
What is DRIO's 1-year price change?
DarioHealth's price fell 90.2% over the past 12 months. With dividends included, the 12-month total return was -90.2%.
What is DRIO's 5-year price change?
DarioHealth's month-end price fell 99.1% over the 5 years through Oct 2026, a compound annual decline of 60.9%. These figures leave out dividends.
What is DRIO's 52-week high and low?
DarioHealth's 52-week high is $14.77 and its 52-week low is $1.09. Its latest price of $1.15 on Nov 17, 2026 is 92.2% below the high.
What is DRIO's beta?
DarioHealth's 1-year beta against the S&P 500 is 0.16, so its price has shown little link to the market's moves over the past year. Its largest fall from a peak over the past year was 91.8%.
Is the DRIO chart free?
Yes. Advanced Charting for DRIO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
DRIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation